Replies to post #36717 on Ariad Pharmaceuticals Inc fka ARIA

[STOCK_GAINER6]

For AP26113 too soon to tell, AP26113 just live from expectations. And BTW, ALK inhibitor market is not the same as in Ponatinib's. But compared to the niche, in which imatinib is, ponantinib has more potential.

[AmpleKind]

pom: "why couldn't 113 have a good chance at being greater than pona?"

It can! Each drug is independent, has to run its own course thru the clinical/regulatory
course, and 113 has shown great efficacy and promise. The Iclusig side effects issue
has no relevance to 113's probability of success.

[gdollasign]

quote

products have gotten better as they come to fruition?

I was waiting for someone to go there....you win my psychology prize. Congratulations